Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosite POC (point-of-care) D-Dimer test:

This article was originally published in Clinica

Executive Summary

Biosite has received US FDA 510(k) clearance to sell its point-of-care (POC) Triage D-Dimer test for helping doctors assess patients suspected of having thromboembolic events, including pulmonary embolism (PE). Portable and easy-to-use, the test can be used in the emergency room (ER) or at the patient's bedside, said the San Diego, California firm. The company added that a recent study showed that a POC clinical protocol for assessing PE, using an available latex-agglutination test for D-Dimer, doubled the number of patients evaluated for the condition and decreased length of stay in the ER, without increasing the need for vascular imaging. At least 650,000 cases of PE occur annually in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel